FDA puts partial hold on CytRx cancer drug trials

LadRx

18/11/2014 11:36

Nov 18 (Reuters) - CytRx Corp  CYTR.O  said the United 
States Food And Drug Administration has placed a partial hold on 
clinical trials of its experimental cancer drug after a patient 
died. 
    CytRx shares were down 10 percent in premarket trading. 
    The patient received the drug, aldoxorubicin, under the 
company's expanded access program that makes promising drugs and 
devices available to patients with serious diseases who cannot 
enroll in clinical trials.  ID:nPn2YrHnp  
    No new patients can be enlisted for the trials, currently in 
mid stage, of aldoxorubicin until the hold is lifted. Patients 
currently enrolled will continue receiving the treatment. 
 
 (Reporting By Rosmi Shaji in Bangalore; Editing by Joyjeet Das) 
 ((Rosmi.Shaji@thomsonreuters.com;)(Within U.S.+1 646 223 8780 
and outside U.S. +91 8067496753)(; Reuters Messaging:  
rosmi.shaji.thomsonreuters.com@reuters.net)) 
 
Keywords: CYTRX FDA/